This week PharmaShots’ news was all about the updates on M&A, Pharma, Clinical Trials, Regulatory & MedTech. Check out our full report below:

Johnson & Johnson Highlights Data from the P-I Study of TAR-210 for Non-Muscle-Invasive Bladder Cancer (NMIBC) at AUA 2024

Read More: Johnson & Johnson                                                                                

UroGen Pharma Reports Real-World Analysis of Jelmyto for Upper Tract Urothelial Carcinoma

Read More: UroGen Pharma                                                                                       

EyePoint Pharmaceuticals Reports the P-II (PAVIA) Study Data of Duravyu for Non-Proliferative Diabetic Retinopathy

Read More: EyePoint Pharmaceuticals                                                                 

Edgewise Therapeutics Reports First Patient Dosing in P-II Study of EDG-7500 to Treat Obstructive Hypertrophic Cardiomyopathy

Read More: Edgewise Therapeutics                                                                       

VYNE Therapeutics Reports the US FDA’s Acceptance of IND for VYN202 to Treat Autoimmune Diseases

Read More:  VYNE Therapeutics                                                                       

Modalis Therapeutics Unveils Epigenome Editing Therapy MDL-101 for Treatment of LAMA2-Deficient CMD

Read More:  Modalis Therapeutics                                                                         

Regeneron Reports Results from the P-I/II (CHORD) Study of DB-OTO for Hearing Loss

Read More:  Regeneron                                                                                           

Acumen Pharmaceuticals Reports First Patient Dosing with Sabirnetug in P-II (ALTITUDE-AD) Study for Early Alzheimer’s Disease

Read More:  Acumen Pharmaceuticals                                                                  

Innovent Biologics Reports the P-III Trial Results of Mazdutide for Treating Type 2 Diabetes

Read More:  Innovent Biologics                                                                            

Merck Reports Results from the P-III (KEYNOTE-B21) Study of Keytruda Plus Chemotherapy for Endometrial Cancer

Read More:  Merck                                                                                            

Fusion Pharmaceuticals Doses First Patient with FPI-2265 in P-II Study for Metastatic Castration-Resistant Prostate Cancer

Read More: Fusion Pharmaceuticals                                                                       

IRLAB Therapeutics Gains the Swedish Medical Products Agency’s Approval to Initiate P-I Trial of IRL757 for Apathy

Read More: IRLAB Therapeutics                                                                               

BMS Reports the US FDA’s Acceptance of BLA for Opdivo to Treat Clear Cell Renal Cell Carcinoma

Read More: BMS                                                                                                        

Innovent’s IBI343 a Monotherapy Receives the NMPA’s Breakthrough Therapy Designation for Advanced Gastric Cancer (GC)

Read More: Innovent                                                                                       

Biotheryx Receives the US FDA’s IND Approval of BTX-9341 for Treating Breast Cancer

Read More: Biotheryx         

SN Bioscience’s SNB-101 Gains the US FDA’s Fast Track Designation for Small Cell Lung Cancer       

Read More: SN Bioscience                        

BioVersys Extends its Strategic Collaboration with GSK and Series C Round by CHF 12.3M

Read More: BioVersys                                                                                                  

IRLAB and McQuade Center for Strategic Research and Development (MSRD) Collaborate to Develop IRL757 for Apathy

Read More: IRLAB & McQuade Center                                                                     

ARTBIO Partners with Nucleus RadioPharma to Manufacture Pb-212 Radiolabeled Therapeutic Products

Read More: ARTBIO & Nucleus RadioPharma                                                      

Flagship Pioneering and Metaphore Biotechnologies Partner with Novo Nordisk to Develop Therapies for Obesity

Read More: Flagship Pioneering, Metaphore Biotechnologies & Novo Nordisk   

Shionogi Partners with Maze Therapeutics for MZE001’s Rights to Treat Pompe Disease 

Read More: Shionogi & Maze Therapeutics

Xbrane Biopharma and STADA Team Up with Valorum Biologics for Commercializing Xlucane (Biosimilar, Ranibizumab) Across the US

Read More: Xbrane Biopharma & STADA

Sanofi Partners with Novavax to Co-commercialize COVID-19 Vaccine and Develop Flu-COVID-19 Combination Vaccines

Read More: Sanofi & Novavax

US Medical Innovations Reports the US FDA’s Clearance of Canady Helios Cold Plasma Ablation System for Soft Tissue Ablation

Read More: US Medical Innovations                                                         

Catalent's Acquisition by Novo Holdings Put on Hold for 30 Days for Antitrust Review

Read More: Catalent & Novo                                                                                   

Arbor Biotechnologies to Acquire Serendipity Biosciences

Read More: Arbor Biotechnologies & Serendipity Biosciences

epiq Animal Health and KeraVet Bio Collaborate to Market KeraVet Gel for Wound Healing in Animals

Read More: epiq Animal Health & KeraVet Bio                                                  

Mozart Therapeutics Highlights Pre-clinical Data of KIR x ICOS CD8 Treg Modulator at Immunology 2024

Read More: Mozart Therapeutics                                                                               

Seragon Biosciences Concludes SRN-901’s Pre-Clinical Study to Evaluate its Effect on Aging

Read More: Seragon Biosciences                                                                                

The US FDA Grants Clearance to Indica Labs’ HALO AP Dx Digital Pathology Platform

Read More: Indica Labs                                             

Related Post:- PharmaShots Weekly Snapshots (April 29 – May 03, 2024)